See more : Hersha Hospitality Trust (HT-PE) Income Statement Analysis – Financial Results
Complete financial analysis of Sierra Oncology, Inc. (SRRA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sierra Oncology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Vitesse Energy, Inc. (VTS) Income Statement Analysis – Financial Results
- Zions Bancorporation, National Association (0M3L.L) Income Statement Analysis – Financial Results
- Badger Infrastructure Solutions Ltd. (BADFF) Income Statement Analysis – Financial Results
- Choice Properties Real Estate Investment Trust (PPRQF) Income Statement Analysis – Financial Results
- Keppel DC REIT (AJBU.SI) Income Statement Analysis – Financial Results
Sierra Oncology, Inc. (SRRA)
About Sierra Oncology, Inc.
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California. As of July 1, 2022, Sierra Oncology, Inc. operates as a subsidiary of GSK plc.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 300.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 300.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 67.15M | 45.12M | 53.25M | 41.08M | 30.16M | 33.90M | 26.36M | 19.08M | 2.84M |
| General & Administrative | 27.44M | 20.12M | 13.74M | 14.34M | 12.46M | 14.18M | 9.47M | 3.50M | 1.16M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 27.44M | 20.12M | 13.74M | 14.34M | 12.46M | 14.18M | 9.47M | 3.50M | 1.16M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 94.59M | 65.24M | 66.99M | 55.42M | 42.62M | 48.08M | 35.83M | 22.58M | 4.01M |
| Cost & Expenses | 94.59M | 65.24M | 66.99M | 55.42M | 42.62M | 48.08M | 35.83M | 22.58M | 4.01M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.72M |
| Depreciation & Amortization | 305.00K | 238.00K | 83.00K | 111.00K | 258.00K | 197.00K | 111.00K | 12.00K | 1.00K |
| EBITDA | -94.36M | -80.52M | -88.35M | -53.53M | -41.60M | -47.53M | -53.09M | -23.86M | -4.11M |
| EBITDA Ratio | 0.00% | -26,840.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -94.66M | -64.94M | -66.99M | -55.42M | -42.62M | -48.08M | -35.83M | -22.58M | -4.01M |
| Operating Income Ratio | 0.00% | -21,647.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 0.00 | -15.82M | -21.44M | 1.78M | 760.00K | 351.00K | -17.38M | -1.29M | -2.83M |
| Income Before Tax | -94.66M | -80.76M | -88.44M | -53.64M | -41.86M | -47.72M | -53.21M | -23.87M | -6.83M |
| Income Before Tax Ratio | 0.00% | -26,920.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -3.00K | 142.00K | -160.00K | -302.00K | 156.00K | 143.00K | 55.00K | 2.00K | -108.00K |
| Net Income | -94.66M | -80.90M | -88.28M | -53.34M | -42.02M | -47.87M | -53.26M | -23.87M | -6.83M |
| Net Income Ratio | 0.00% | -26,967.33% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -7.14 | -7.70 | -30.30 | -30.16 | -33.68 | -63.32 | -147.95 | -56.76 | -13.19 |
| EPS Diluted | -7.14 | -7.70 | -30.30 | -30.16 | -33.68 | -63.32 | -147.95 | -56.76 | -13.19 |
| Weighted Avg Shares Out | 13.25M | 10.51M | 2.91M | 1.77M | 1.25M | 756.01K | 359.99K | 420.57K | 518.10K |
| Weighted Avg Shares Out (Dil) | 13.25M | 10.51M | 2.91M | 1.77M | 1.25M | 756.01K | 359.99K | 420.57K | 518.10K |
GSK Receives Regulatory Nod for Consumer Healthcare Demerger
SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sierra Oncology, Inc - SRRA
SIERRA ONCOLOGY INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Sierra Oncology, Inc - SRRA
Best Biotech Stocks To Buy Now? 5 To Know
SHAREHOLDER ALERT: Weiss Law Investigates Sierra Oncology, Inc.
Late-Stage Biopharmaceutical Sierra Oncology announces acquisition by GSK
Why Is Sierra Oncology (SRRA) Stock Up Today?
Sierra Oncology Stock Is Soaring: Here's Why
Sierra Oncology Stock Soars After Buyout
GSK to buy Sierra Oncology for $1.9 billion
Source: https://incomestatements.info
Category: Stock Reports